Cargando…

Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach

BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also...

Descripción completa

Detalles Bibliográficos
Autores principales: Caiola, Elisa, Falcetta, Francesca, Giordano, Silvia, Marabese, Mirko, Garassino, Marina C., Broggini, Massimo, Pastorelli, Roberta, Brunelli, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/
https://www.ncbi.nlm.nih.gov/pubmed/30514331
http://dx.doi.org/10.1186/s13046-018-0954-5
_version_ 1783378681450725376
author Caiola, Elisa
Falcetta, Francesca
Giordano, Silvia
Marabese, Mirko
Garassino, Marina C.
Broggini, Massimo
Pastorelli, Roberta
Brunelli, Laura
author_facet Caiola, Elisa
Falcetta, Francesca
Giordano, Silvia
Marabese, Mirko
Garassino, Marina C.
Broggini, Massimo
Pastorelli, Roberta
Brunelli, Laura
author_sort Caiola, Elisa
collection PubMed
description BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also have deletions or inactivating mutations in the serine/threonine kinase 11 (LKB1) gene. Loss of LKB1 on a KRAS-mutant background may represent a significant source of heterogeneity contributing to poor response to therapy. METHODS: Here, we employed an integrated multilevel proteomics, metabolomics and functional in-vitro approach in NSCLC H1299 isogenic cells to define their metabolic state associated with the presence of different genetic background. Protein levels were obtained by label free and single reaction monitoring (SRM)-based proteomics. The metabolic state was studied coupling targeted and untargeted mass spectrometry (MS) strategy. In vitro metabolic dependencies were evaluated using 2-deoxy glucose (2-DG) treatment or glucose/glutamine nutrient limitation. RESULTS: Here we demonstrate that co-occurring KRAS mutation/LKB1 loss in NSCLC cells allowed efficient exploitation of glycolysis and oxidative phosphorylation, when compared to cells with each single oncologic genotype. The enhanced metabolic activity rendered the viability of cells with both genetic lesions susceptible towards nutrient limitation. CONCLUSIONS: Co-occurrence of KRAS mutation and LKB1 loss in NSCLC cells induced an enhanced metabolic activity mirrored by a growth rate vulnerability under limited nutrient conditions relative to cells with the single oncogenetic lesions. Our results hint at the possibility that energy stress induced by calorie restriction regimens may sensitize NSCLCs with these co-occurring lesions to cytotoxic chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0954-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6280460
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62804602018-12-10 Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach Caiola, Elisa Falcetta, Francesca Giordano, Silvia Marabese, Mirko Garassino, Marina C. Broggini, Massimo Pastorelli, Roberta Brunelli, Laura J Exp Clin Cancer Res Research BACKGROUND: Non–small-cell lung cancer (NSCLC) is a heterogeneous disease, with multiple different oncogenic mutations. Approximately 25–30% of NSCLC patients present KRAS mutations, which confer poor prognosis and high risk of tumor recurrence. About half of NSCLCs with activating KRAS lesions also have deletions or inactivating mutations in the serine/threonine kinase 11 (LKB1) gene. Loss of LKB1 on a KRAS-mutant background may represent a significant source of heterogeneity contributing to poor response to therapy. METHODS: Here, we employed an integrated multilevel proteomics, metabolomics and functional in-vitro approach in NSCLC H1299 isogenic cells to define their metabolic state associated with the presence of different genetic background. Protein levels were obtained by label free and single reaction monitoring (SRM)-based proteomics. The metabolic state was studied coupling targeted and untargeted mass spectrometry (MS) strategy. In vitro metabolic dependencies were evaluated using 2-deoxy glucose (2-DG) treatment or glucose/glutamine nutrient limitation. RESULTS: Here we demonstrate that co-occurring KRAS mutation/LKB1 loss in NSCLC cells allowed efficient exploitation of glycolysis and oxidative phosphorylation, when compared to cells with each single oncologic genotype. The enhanced metabolic activity rendered the viability of cells with both genetic lesions susceptible towards nutrient limitation. CONCLUSIONS: Co-occurrence of KRAS mutation and LKB1 loss in NSCLC cells induced an enhanced metabolic activity mirrored by a growth rate vulnerability under limited nutrient conditions relative to cells with the single oncogenetic lesions. Our results hint at the possibility that energy stress induced by calorie restriction regimens may sensitize NSCLCs with these co-occurring lesions to cytotoxic chemotherapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13046-018-0954-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-12-04 /pmc/articles/PMC6280460/ /pubmed/30514331 http://dx.doi.org/10.1186/s13046-018-0954-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Caiola, Elisa
Falcetta, Francesca
Giordano, Silvia
Marabese, Mirko
Garassino, Marina C.
Broggini, Massimo
Pastorelli, Roberta
Brunelli, Laura
Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
title Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
title_full Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
title_fullStr Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
title_full_unstemmed Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
title_short Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
title_sort co-occurring kras mutation/lkb1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280460/
https://www.ncbi.nlm.nih.gov/pubmed/30514331
http://dx.doi.org/10.1186/s13046-018-0954-5
work_keys_str_mv AT caiolaelisa cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT falcettafrancesca cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT giordanosilvia cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT marabesemirko cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT garassinomarinac cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT brogginimassimo cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT pastorelliroberta cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach
AT brunellilaura cooccurringkrasmutationlkb1lossinnonsmallcelllungcancercellsresultsinenhancedmetabolicactivitysusceptibletocaloricrestrictionaninvitrointegratedmultilevelapproach